Vaccine myocarditis risk reaches 1 in 10,000 for adolescent boys But while the rate of Pfizer-related myocarditis continues to increase in males aged 12–17, research cited by the TGA indicates the risk is still dwarfed by the threat COVID-19 poses to this cohort.
TGA updates post-COVID vaccine myocarditis rates As many of Australia’s remaining vaccine-hesitant patients express concerns over rare side effects associated with mRNA vaccines, the TGA has broken down rates of myocarditis cases following Pfizer doses.
TGA monitoring overseas Moderna recommendations Several countries have limited the use of the mRNA vaccine in younger people, but there is no sign Australia will institute a similar pause.
Adolescents at most risk of developing myocarditis: TGA Myocarditis rates related to the Pfizer vaccine been released, while the Moderna vaccine has been included in the safety report for the first time.
Five further blood clot cases linked to AstraZeneca The latest TGA safety report also confirms no vaccine-related fatalities have occurred in the past week, in stark contrast to 62 COVID deaths.
Doubts over study linking mRNA vaccines and adolescents’ myocarditis risk A study co-author has been connected to an online group opposing pandemic public health measures, from mask-wearing and lockdowns to mandatory vaccinations.
Two more AstraZeneca-linked deaths in past week: TGA The latest fatalities mean Australia has now recorded nine deaths linked to the vaccine, compared to more than 1000 COVID deaths.
NZ myocarditis death had probable link to Pfizer vaccine But a recent real-world study on the vaccine’s safety – the largest undertaken to date – has found people are four times more likely to develop the condition if they become infected with COVID-19.
Guillain-Barre Syndrome warning for AstraZeneca The TGA has updated the vaccine’s Product Information regarding the ‘very rare’ possibility of contracting the disorder.
TGA updates Pfizer vaccine side effect information Myocarditis and pericarditis were listed as official adverse reactions on the same day the vaccine was approved for use in children aged 12–15.